Učitavanje...
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Mutational profiling has fundamentally changed our approach to patients with acute myeloid leukemia (AML). Patients with AML are routinely profiled for the presence of mutations in FLT3, NPM1, CEBPA, and, more recently, TP53. In this chapter, we review the role of mutational profiling to help define...
Spremljeno u:
| Izdano u: | Blood Adv |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6234366/ https://ncbi.nlm.nih.gov/pubmed/30425072 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018020206 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|